

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/007248-2021>

Tender

Project Manager/BSL3 Laboratory – Full and complete service for the duration of the project life cycle Validation Centre

Medicines Discovery Catapult

F02: Contract notice

Notice identifier: 2021/S 000-007248

Procurement identifier (OCID): ocds-h6vhtk-02a3c1

Published 8 April 2021, 1:59pm

Section I: Contracting authority

I.1) Name and addresses

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Cheshire

SK10 4TG

Contact

Mr Kieran McGowan

Email

Kieran.McGowan@md.catapult.org.uk

Telephone

+44 1625708394

Country

United Kingdom

NUTS code

UKD62 - Cheshire East

Internet address(es)

Main address

<https://md.catapult.org.uk/>

Buyer's address

<https://md.catapult.org.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=0b0b42be-5298-eb11-810c-005056b64545#>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=0b0b42be-5298-eb11-810c-005056b64545#>

I.4) Type of the contracting authority

Other type

Research - Drug Discovery / Health

I.5) Main activity

Other activity

Research - Drug Discovery / Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Project Manager/BSL3 Laboratory – Full and complete service for the duration of the project life cycle Validation Centre

Reference number

DN536830

II.1.2) Main CPV code

- 45000000 - Construction work

II.1.3) Type of contract

Works

II.1.4) Short description

Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK's onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.

The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.

Project Manager: Further information can be found at <https://procontract.due-north.com/RFx/RFxSummary?rfxId=0b0b42be-5298-eb11-810c-005056b64545#>

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 71000000 - Architectural, construction, engineering and inspection services

II.2.3) Place of performance

NUTS codes

- UKD62 - Cheshire East

II.2.4) Description of the procurement

Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK's onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.

The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and

global need. The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.

Project Manager: Further information can be found at <https://procontract.due-north.com/RFx/RFxSummary?rfxId=0b0b42be-5298-eb11-810c-005056b64545#>

II.2.5) Award criteria

Quality criterion - Name: Price is not the only award criterion and all criteria are stated only in the procurement documents. / Weighting: 80

Price - Weighting: 20

II.2.6) Estimated value

Value excluding VAT: £55,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

12

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

30 April 2021

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date

30 April 2021

Local time

12:05pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Macclesfield

SK10 4TG

Email

kieran.mcgowan@md.catapult.org.uk

Country

United Kingdom